Exelixis (NASDAQ:EXEL – Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16), Briefing.com reports. The company had revenue of $425.23 million during the quarter, compared to analysts’ expectations of $461.04 million. Exelixis had a return on equity […]
Rexel reports sales of 4.71 billion euros for the first three months of 2024, down 4.6% on a constant-day basis, in line with expectations, due to a high base effect linked to electrification.
European stocks were subdued on Tuesday as investors looked forward to the Federal Reserve providing an update on when interest rates might be cut. The downside remained capped as preliminary flash estimate from Eurostat showed that the euro area economy expanded in the first quarter after two consecutive declines.